Adaptin Bio (APTN) Common Equity (2022 - 2026)

Adaptin Bio has disclosed Common Equity across 5 years of filings, most recently posting -$1.7 million for Q2 2026.

• In Q2 2026, Common Equity fell 451.04% year-over-year to -$1.7 million; the TTM figure through Jun 2026 stood at -$1.7 million (down 451.04% YoY), while the FY2025 annual figure was -$1.5 million, up 63.67% from the prior year.
• Common Equity came in at -$1.7 million for Q2 2026 at Adaptin Bio, up from -$1.8 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.7 million in Q1 2025 to a low of -$4.1 million in Q4 2024.
• Average Common Equity over 5 years is -$1.2 million, with a median of -$1.3 million recorded in 2024.
• Year-over-year, Common Equity plunged 4018.87% in 2024 and jumped 232.52% in 2025.
• Over 5 years, Common Equity stood at -$27304.0 in 2022, then slumped by 3480.28% to -$977559.0 in 2023, then slumped by 319.42% to -$4.1 million in 2024, then surged by 63.67% to -$1.5 million in 2025, then dropped by 11.81% to -$1.7 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were -$1.7 million in Q2 2026, -$1.8 million in Q1 2026, and -$1.5 million in Q4 2025.